Bausch + Lomb Corporation (BLCO) carries a Roarable Rating of C- (Hold) with 59/100 RQD Confidence. The underlying business is intact, so current owners don’t need to panic-sell—but mixed big-money flow or rich pricing means new buyers can afford to wait for either a pullback or a B-or-higher upgrade.
Bausch + Lomb Corporation (BLCO) slipped 0.00% to $20.40 as options desks priced 55% call premium vs. 45% put protection around the $20 max-pain magnet. Solid 41% profit margin (1% return on capital), mixed timing at current multiples—hold if owned, no rush to chase.
Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.
Bausch + Lomb stock walked into this Q3 2026 report quietly, flat at US$20.40 and up only modestly over the past quarter. The share price barely flinched after the release. The earnings story did not. Management reported
JP Morgan analyst Robbie Marcus maintains Bausch & Lomb (NYSE:BLCO) with a Neutral and raises the price target from $16 to $22.
RBC Capital analyst Douglas Miehm maintains Bausch & Lomb (NYSE:BLCO) with a Outperform and raises the price target from $21 to $23.
Key TakeawaysBausch Health jumped 21% after adjusted EPS of $1. 77 beat estimates, and it raised its outlook again.
Bausch Health shares jump 9% as Q3 earnings top estimates, driven by Xifaxan-led Salix growth, improved profitability and raised 2026 guidance.
VAUGHAN, Ontario, October 29, 2026--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the publication of results from a
Wells Fargo analyst Larry Biegelsen maintains Bausch & Lomb (NYSE:BLCO) with a Equal-Weight and raises the price target from $18 to $19.
Bausch + Lomb (NYSE:BLCO) reported third-quarter revenue growth across all three business segments, raised its full-year outlook for the third time in 2026 and highlighted continued margin expansion and cash generation a
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +6.5% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on BLCO today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for BLCO. Explore sector supply chains on /butterfly.
Why BLCO Stock Traded Steady Today — RQD Quant Desk Flash. Solid 41% profit margin (1% return on capital), mixed timing at current multiples—hold if owned, no rush to chase.